EGFR and non-small cell lung carcinoma: Of the 15 patients with NSCLC, 33.3% (5/15) received EGFR-targeting tyrosine kinase inhibitors (erlotinib, afatinib, osimertinib, lapatinib) at some time after diagnosis of BM.